295 related articles for article (PubMed ID: 22245478)
1. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure.
Kasama S; Toyama T; Sumino H; Kumakura H; Takayama Y; Minami K; Ichikawa S; Matsumoto N; Sato Y; Kurabayashi M
Int J Cardiol; 2013 Jul; 167(1):244-9. PubMed ID: 22245478
[TBL] [Abstract][Full Text] [Related]
2. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
Kasama S; Toyama T; Sumino H; Matsumoto N; Sato Y; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2007 Dec; 48(12):1993-2000. PubMed ID: 18006623
[TBL] [Abstract][Full Text] [Related]
3. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Am Coll Cardiol; 2003 Feb; 41(4):574-81. PubMed ID: 12598068
[TBL] [Abstract][Full Text] [Related]
4. Effects of statin therapy on cardiac sympathetic nerve activity and left ventricular remodeling in patients with chronic heart failure: a propensity score-matched analysis.
Sano H; Kasama S; Fujimoto S; Toyama T; Takama N; Koitabashi N; Ichikawa S; Suzuki Y; Matsumoto N; Sato Y; Kurabayashi M
Medicine (Baltimore); 2014 Dec; 93(27):e214. PubMed ID: 25501081
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral nicorandil therapy on sympathetic nerve activity and cardiac events in patients with chronic heart failure: subanalysis of our previous report using propensity score matching.
Kasama S; Toyama T; Iwasaki T; Sumino H; Kumakura H; Minami K; Ichikawa S; Matsumoto N; Sato Y; Kurabayashi M
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):144-54. PubMed ID: 23982455
[TBL] [Abstract][Full Text] [Related]
6. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Am Coll Cardiol; 2005 Mar; 45(5):661-7. PubMed ID: 15734608
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction.
Kasama S; Toyama T; Sumino H; Nakazawa M; Matsumoto N; Sato Y; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2008 Jun; 49(6):907-14. PubMed ID: 18483106
[TBL] [Abstract][Full Text] [Related]
8. Assessment of therapeutic effects of statin on cardiac sympathetic nerve activity and cardiac events in patients with ischemic cardiomyopathy and mild to moderate heart failure.
Kasama S; Toyama T; Suzuki S; Ito Y; Matsumoto N; Kurabayashi M; Kasahara M
Nucl Med Commun; 2019 Feb; 40(2):159-168. PubMed ID: 30461696
[TBL] [Abstract][Full Text] [Related]
9. Serial cardiac 123I-metaiodobenzylguanidine scintigraphic studies are more useful for predicting cardiac death than one-time scan in patients with chronic heart failure: sub-analysis of our previous report.
Kasama S; Toyama T; Sumino H; Kumakura H; Takayama Y; Minami K; Ichikawa S; Matsumoto N; Sato Y; Kurabayashi M
Nucl Med Commun; 2010 Sep; 31(9):807-13. PubMed ID: 20543756
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].
Skvortsov AA; Mareev VY; Chelmakina SM; Baklanova NA; Belenkov IuN
Kardiologiia; 2007; 47(10):12-23. PubMed ID: 18260939
[TBL] [Abstract][Full Text] [Related]
11. [Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction].
Tsutamoto T
Nihon Yakurigaku Zasshi; 2004 Aug; 124(2):90-100. PubMed ID: 15277727
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2002 Oct; 43(10):1279-85. PubMed ID: 12368364
[TBL] [Abstract][Full Text] [Related]
13. Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction.
Kasama S; Toyama T; Sumino H; Kumakura H; Takayama Y; Minami K; Ichikawa S; Matsumoto N; Sato Y; Kurabayashi M
Heart; 2011 May; 97(10):817-22. PubMed ID: 21378011
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
[TBL] [Abstract][Full Text] [Related]
15. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
Krum H; Mohacsi P; Katus HA; Tendera M; Rouleau JL; Fowler MB; Coats AJ; Roecker EB; Packer M;
Am Heart J; 2006 Jan; 151(1):55-61. PubMed ID: 16368292
[TBL] [Abstract][Full Text] [Related]
16. Adherence to aldosterone-blocking agents in patients with heart failure.
Margolis J; Gerber RA; Roberts C; Gheorghiade M
Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
[TBL] [Abstract][Full Text] [Related]
17. [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].
Skvortsov AA; Mareev VIu; Orlova IaA; Chelmakina SM; Baklanova NA; Belenkov IuN
Kardiologiia; 2008; 48(2):52-64. PubMed ID: 18261010
[TBL] [Abstract][Full Text] [Related]
18. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
[TBL] [Abstract][Full Text] [Related]
19. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
Cohen JB; Schrauben SJ; Zhao L; Basso MD; Cvijic ME; Li Z; Yarde M; Wang Z; Bhattacharya PT; Chirinos DA; Prenner S; Zamani P; Seiffert DA; Car BD; Gordon DA; Margulies K; Cappola T; Chirinos JA
JACC Heart Fail; 2020 Mar; 8(3):172-184. PubMed ID: 31926856
[TBL] [Abstract][Full Text] [Related]
20. [Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
Tatsumi T; Matsubara H
Nihon Rinsho; 2006 Jul; 64 Suppl 5():524-9. PubMed ID: 16897886
[No Abstract] [Full Text] [Related]
[Next] [New Search]
